Showing 3511-3520 of 18631 results for "".
Are All VMAT2s The Same? Data Driven Treatment Decisions for Tardive Dyskinesia
https://reachmd.com/programs/cme/are-all-vmat2s-the-same-data-driven-treatment-decisions-for-tardive-dyskinesia/36174/Join us to learn about the emerging data with VMAT2 inhibitors for the treatment of tardive dyskinesia.Mastering the Sequence: CELMoDs Across Treatment Lines
https://reachmd.com/programs/cme/mastering-the-sequence-celmods-across-treatment-lines/36570/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityRAS Across Tumors: Who to Test When
https://reachmd.com/programs/cme/ras-across-tumors-who-to-test-when/54117/Explore ON-state RAS inhibitors for the treatment of NSCLC and pancreatic cancer, including mechanisms, efficacy data, and integration into clinical practice.Primary HPV Screening: A Nurse Practitioner’s Perspective
https://reachmd.com/programs/video-library/primary-hpv-screening-nurse-practitioners-perspective/8593/The following is part of a 3-part-video series addressing clinician-patient interactions related to primary high-risk HPV screening. More specifically, this video represents a typical dialogue between a Nurse Practitioner and her patient as she explains primary high-risk HPV screening to her patientAdvancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/Experts explain how emerging clinical data and novel therapeutic strategies in HNSCC can expand our treatment armamentarium and improve patient outcomes.Driving Progress in Cardiology: Exploring the Role of FXI in Acute Coronary Syndromes & Beyond
https://reachmd.com/programs/cme/driving-progress-in-cardiology-exploring-the-role-of-fxi-in-acute-coronary-syndromes-beyond/32980/Don’t miss this broadcast replay on the potential role of factor XI inhibition in acute coronary syndrome, Afib, and secondary stroke prevention.Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
https://reachmd.com/programs/cme/optimizing-raasimra-therapy-in-patients-with-heart-failure-ckd-and-hyperkalemia-a-microlearning-curriculum-approach/26750/Learn from a multidisciplinary faculty panel how to Improve outcomes for patients with CKD and HFrEF using optimal RAASi and MRAs while managing hyperkalemia with potassium binders.Safety First: Navigating CELMoD-Associated Toxicities
https://reachmd.com/programs/cme/safety-first-navigating-celmod-associated-toxicities/36571/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma ActivityTau and Neurodegeneration in Alzheimer’s Disease: Bridging Pathology and Clinical Progression Through Biomarkers
https://reachmd.com/programs/medical-industry-feature/tau-neurodegeneration-alzheimers-biomarkers/37875/For the latest insights on tau and neurodegeneration biomarkers in Alzheimer’s disease (AD), tune in to this recorded presentation featuring Doctor Michelle Mielke and Professor Henrik Zetterberg. Together, they delve into the role of tau in AD, exploring the ‘tau cascade’, the current use of tau aPrecision Targeting: Matching CELMoDs to the Right Patient With Myeloma
https://reachmd.com/programs/cme/precision-targeting-matching-celmods-to-the-right-patient-with-myeloma/36569/Beyond the Horizon in Multiple Myeloma: Harnessing Novel CELMoD Mechanisms for Increased Antimyeloma Activity